Condition
Broader IBD news covering Crohn's disease, ulcerative colitis, research, treatments, monitoring, and patient care.
Page 23 of 88 · 4183 articles
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
Patients and clinicians often need evidence about whether switching from ustekinumab to an anti‑TNF (infliximab or adalimumab) still gives meaningful clinical responses. This study suggests many patients can respond, but...
Obese patients with FibroScan-detected steatosis in this cohort had a high frequency of colitis and some cases of IBD, dysplasia, and cancer, which could affect screening and symptom evaluation decisions.
Malnutrition was common in this group and linked to lower fistula healing and a higher chance of needing proctectomy or abdominal surgery — outcomes that matter to people with perianal Crohn’s disease.
Refractory IBD in children is linked to growth and development problems, hospitalizations, and surgery; knowing treatment options after anti‑TNF failure matters for long‑term outcomes. The review highlights which...
HBV reactivation is a preventable but serious complication of chemotherapy and immunosuppression; this study shows low awareness and screening in Belgian specialists, suggesting patients starting immunosuppression may be...
FDA IND clearance lets PALI‑2108 move into a Phase 2 trial in Crohn’s disease, meaning the drug’s safety and efficacy will be formally tested in people with moderate-to-severe disease. The program is being run alongside...
A pro athlete’s experience with perianal Crohn’s disease shows how chronic pain and major surgery can disrupt training and life, and offers practical strategies (advocacy, rehab, pacing) that other people with IBD may...
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
Fatigue is extremely common in IBD and is closely linked to depression—recognizing and addressing mental-health issues may be important for patients who report significant fatigue.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from American journal of...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from International Journal...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and CRP. The original article is from Journal of medical biochemistry.
The study connects many IBD genetic risk regions to specific genes and cell types, helping prioritize drug targets. It also nominates a known small molecule (entrectinib) as a repurposing candidate via NLRP3/NEK7...
This study directly compares two rescue medications used when intravenous steroids fail in acute severe ulcerative colitis, reporting similar short-term remission and safety but a slower early response with tacrolimus —...
This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Sulfasalazine. The original article is from Pediatric Gastroenterology,...
Preclinical data suggest blocking STAT3 with TTI-101 prevented colitis-associated colorectal tumors in a mouse model and altered tumor-related gene expression and the gut microbiome — findings that could guide future...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease and Research and clinical trials. The original article is from Frontiers in...
FDA clearance lets Palisade start a Phase 2 trial of PALI-2108 in moderate-to-severe Crohn’s disease, which could matter to patients and clinicians watching new oral treatments targeted to the lower intestine.
Based on the title and source metadata, this appears to be a case report related to Inflammatory bowel disease and Procedures and surgery. The original article is from ACG case reports journal.
AI tools for endoscopic and multimodal IBD assessment could make scoring and monitoring more objective and consistent, which matters for treatment decisions and tracking remission or relapse. The review also flags...
Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Biomarkers. The original article is from Digestive and liver disease :...
Fibrotic strictures in Crohn’s disease often don’t respond to medication and may need endoscopic or surgical treatment. This trial directly compares two endoscopic options to see which is safer and more effective at...
Fibrotic strictures are a major cause of symptoms and surgery in Crohn’s disease; an oral anti‑fibrotic drug could offer a non‑surgical treatment option if trials show benefit and safety. This study tests RXC008...
A new oral investigational drug (TP317) is entering a Phase 1b study in adults with active UC to assess safety and pharmacokinetics, which may be relevant to patients seeking information about emerging therapies.
Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...
This study describes a new nanoparticle (Ce‑TA) that reduced inflammation and tissue injury in a common mouse model of colitis, suggesting a possible future therapeutic avenue for IBD driven by antioxidant and...
Strictures cause obstructive symptoms and repeat surgery in Crohn’s disease; endoscopic options can relieve obstruction and potentially avoid or postpone surgery for some patients.
If disease activity hurts quality of life partly through low self-efficacy and (for UC) psychological distress, then boosting self-management confidence and identifying anxiety/depression could help improve...
A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.
Biologics can be critical for treating moderate-to-severe IBD, but cost and treatment failure limit access and long‑term use in this Indian cohort. Understanding uptake and reasons for stopping helps target interventions...
Patient engagement in treatment decisions can affect satisfaction, adherence, and care planning. This study identifies practical factors (treatment options, trusted providers, community support) associated with higher...
The study suggests quercetin can reduce inflammation and tissue damage markers in lab models of ulcerative colitis, pointing to ERK–MMP signaling as a possible mechanism. That could inform future preclinical research...
VEO-IBD often presents with severe, extensive disease and can include monogenic causes and early hepatobiliary complications; knowing common presentations and early management patterns helps families and clinicians plan...
People diagnosed as IBDU want to know whether their disease course, treatment needs, and chance of later being reclassified differ from typical UC or Crohn's disease.
The study targets TLR2 activation by bacterial curli, a mechanism linked to inflammation in IBD and other immune conditions. Engineering curli to inhibit TLR2 could become a strategy to create probiotics that reduce...
Disability and functional limitations (school, sports, travel, diet) are common early after pediatric IBD diagnosis and can persist for some children even after clinical remission. Recognizing and measuring disability...
A formulation that increases oral absorption of quercetin and reduces inflammation in animal models could point toward new flavonoid-based therapies for ulcerative colitis, but findings are preclinical.
Identifies IL-1RN and SERPINA1 as biomarkers linked to macrophage-driven inflammation in ulcerative colitis and shows TolDCs can reduce macrophage pro-inflammatory cytokine expression in lab experiments — findings that...
The study suggests that higher levels of objectively measured moderate-to-vigorous physical activity are associated with lower risk of developing ulcerative colitis, and that people may gain similar associations whether...
The study compares ustekinumab effectiveness between biologic‑naïve and biologic‑experienced Crohn’s patients and links clinical response to better quality of life and reduced anxiety — information relevant when...
The study reports that kaempferol reduced inflammation, fibrosis, and barrier damage in mouse and cell models of colitis — mechanisms directly relevant to IBD progression and symptoms.
Predicting which children with Crohn disease will need surgery — and roughly when — could help families and clinicians plan treatments, monitoring, and discussions about elective bowel resection earlier in the disease...
A non-invasive MRI method that correlates with histology and endoscopic scores could reduce the need for frequent colonoscopy for assessing IBD activity and help monitor treatment response, especially when endoscopy is...
People with IBD may be concerned about environmental exposures that could influence inflammation or worsen disease. This review explains why micro- and nanoplastics are biologically plausible contributors but also why...
The study proposes a new immunomodulatory approach—phosphatidylserine liposomes—that reduced inflammation in mouse colitis models and altered monocyte and T-cell responses, which could point toward future therapies for...
